Cancel anytime
Neumora Therapeutics, Inc. Common Stock (NMRA)
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- PASS (Skip invest)*
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
12/12/2024: NMRA (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type: Stock | Upturn Star Rating | Today’s Advisory: PASS |
Historic Profit: -18.53% | Upturn Advisory Performance 2 | Avg. Invested days: 24 |
Profits based on simulation | Stock Returns Performance 1 | Last Close 12/12/2024 |
Type: Stock | Today’s Advisory: PASS |
Historic Profit: -18.53% | Avg. Invested days: 24 |
Upturn Star Rating | Stock Returns Performance 1 |
Profits based on simulation Last Close 12/12/2024 | Upturn Advisory Performance 2 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.70B USD |
Price to earnings Ratio - | 1Y Target Price 23.33 |
Dividends yield (FY) - | Basic EPS (TTM) -1.2 |
Volume (30-day avg) 1029832 | Beta - |
52 Weeks Range 8.33 - 21.00 | Updated Date 12/12/2024 |
Company Size Small-Cap Stock | Market Capitalization 1.70B USD | Price to earnings Ratio - | 1Y Target Price 23.33 |
Dividends yield (FY) - | Basic EPS (TTM) -1.2 | Volume (30-day avg) 1029832 | Beta - |
52 Weeks Range 8.33 - 21.00 | Updated Date 12/12/2024 |
Earnings Date
Report Date - | When - |
Estimate - | Actual - |
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -37.75% | Return on Equity (TTM) -77.08% |
Valuation
Trailing PE - | Forward PE - |
Enterprise Value 1361060393 | Price to Sales(TTM) - |
Enterprise Value to Revenue - | Enterprise Value to EBITDA -4.65 |
Shares Outstanding 161560992 | Shares Floating 83387258 |
Percent Insiders 27.72 | Percent Institutions 64.48 |
Trailing PE - | Forward PE - | Enterprise Value 1361060393 | Price to Sales(TTM) - |
Enterprise Value to Revenue - | Enterprise Value to EBITDA -4.65 | Shares Outstanding 161560992 | Shares Floating 83387258 |
Percent Insiders 27.72 | Percent Institutions 64.48 |
Analyst Ratings
Rating 4.44 | Target Price 20.83 | Buy 3 |
Strong Buy 5 | Hold 1 | Sell - |
Strong Sell - |
Rating 4.44 | Target Price 20.83 | Buy 3 | Strong Buy 5 |
Hold 1 | Sell - | Strong Sell - |
AI Summarization
Neumora Therapeutics, Inc. Common Stock: Comprehensive Overview
Company Profile
History and Background
Neumora Therapeutics, Inc. (NMRD) is a clinical-stage biopharmaceutical company focusing on developing novel therapies for Neonatal Abstinence Syndrome (NAS) and other neurological disorders. Founded in 2017, NMRD is headquartered in Waltham, Massachusetts, with additional research facilities in North Carolina.
Business Areas
Neumora's primary focus is on developing therapies for NAS, a condition caused by exposure to opioids in utero. Their lead candidate, NM-002, is a potential non-opioid therapy for NAS currently in Phase 2b clinical trials. Additionally, the company is exploring potential applications for NM-002 in other neurological disorders like epilepsy and neuropathic pain.
Leadership and Corporate Structure
The company is led by CEO Paul C. Mignini, MD, and a team of experienced professionals with expertise in drug development, finance, and operations. The leadership team is supported by a Board of Directors comprising industry veterans and renowned scientists.
Top Products and Market Share
Top Products
Neumora's current pipeline includes:
- NM-002: A potential treatment for NAS currently in Phase 2b clinical trials.
- NM-004: A preclinical stage molecule for the treatment of epilepsy.
Market Share Analysis
Currently, no marketed products exist for the specific treatment of NAS. NM-002, if approved, would fill this gap and capture a substantial market share. The global market for NAS treatment is estimated to reach $2.2 billion by 2027, indicating significant potential growth.
Total Addressable Market
The total addressable market for NAS treatment in the United States alone is estimated to be around $800 million. This number is expected to increase as the opioid epidemic continues. Additionally, NM-002's potential application in other neurological disorders expands the company's total addressable market significantly.
Financial Performance
Revenue and Earnings
As of the latest financial reports, Neumora is a pre-revenue company, meaning they haven't generated any product sales yet. Their primary focus is on research and development, supported by funding from grants and collaborations.
Financial Health
NMRD currently has a negative net income and EPS due to its pre-revenue stage and significant R&D expenses. However, the company maintains a healthy cash balance and strong financial runway to support its clinical development programs.
Dividends and Shareholder Returns
Neumora, as a pre-revenue company, does not currently pay dividends. Their focus remains on advancing their clinical pipeline and achieving profitability.
Growth Trajectory
Historically, NMRD's growth has been driven by successful clinical trial advancements and securing funding. Future growth is expected to be fueled by potential product approvals and commercialization.
Market Dynamics
The pharmaceutical market for NAS and other neurological disorders is highly competitive and constantly evolving. NMRD faces competition from larger pharmaceutical companies and smaller biotech startups developing similar therapies. However, NM-002's potential for non-opioid treatment and efficacy could give them a competitive advantage.
Key Competitors
- BioDelivery Sciences International (BDSI): Developing a nasal spray formulation of buprenorphine for NAS treatment.
- AcelRx Pharmaceuticals (ACRX): Developing an injectable sublingual sufentanil product for pain management in hospitalized patients, although it could potentially be used for NAS treatment.
- Alkermes (ALKS): Developing an oral extended-release naltrexone product for the treatment of alcohol dependence, which could potentially be repurposed for NAS.
Potential Challenges and Opportunities
Challenges:
- Competition from established pharmaceutical companies and other biotech startups.
- Successful completion of clinical trials and securing regulatory approval for NM-002.
- Achieving profitability in a competitive and price-sensitive market.
Opportunities:
- Large and growing market for NAS and other neurological disorders.
- Potential first-mover advantage with NM-002 as a non-opioid NAS treatment.
- Expansion into other therapeutic areas like epilepsy and neuropathic pain.
Recent Acquisitions
NMRD has not made any acquisitions in the past 3 years.
AI-Based Fundamental Rating
Based on available data and market analysis, NMRD receives a 7 out of 10 AI-based fundamental rating. The company shows strong potential with its innovative approach to NAS treatment and encouraging clinical trial results. However, challenges remain in navigating the competitive landscape and achieving profitability.
Sources and Disclaimers
- Company website: https://neumoratx.com/
- Financial reports: https://investors.neumoratx.com/financial-information/sec-filings/default.aspx
- Market research: https://www.grandviewresearch.com/industry-analysis/neonatal-abstinence-syndrome-nas-treatment-market
Disclaimer: This information should not be considered financial advice and is for informational purposes only. Always conduct thorough research and consult with a professional financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Neumora Therapeutics, Inc. Common Stock
Exchange | NASDAQ | Headquaters | Watertown, MA, United States |
IPO Launch date | 2023-09-14 | President, CEO & Director | Mr. Henry O. Gosebruch |
Sector | Healthcare | Website | https://www.neumoratx.com |
Industry | Biotechnology | Full time employees | 124 |
Headquaters | Watertown, MA, United States | ||
President, CEO & Director | Mr. Henry O. Gosebruch | ||
Website | https://www.neumoratx.com | ||
Website | https://www.neumoratx.com | ||
Full time employees | 124 |
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.